Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Maintains $1152 Price Target

Author: Benzinga Newsdesk | June 27, 2024 09:41am
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and maintains $1152 price target.

Posted In: REGN